Financial Performance - The company achieved a revenue of CNY 1.163 billion in the first half of 2025, representing a year-on-year growth of 30.38% [2] - The net profit attributable to shareholders reached CNY 335 million, marking a significant increase of 97.75% compared to the same period last year [2] Dividend Distribution - The board approved a cash dividend plan of CNY 7 per 10 shares based on a total share capital of 245 million shares, pending approval at the upcoming shareholder meeting [3] Product Promotion and Market Strategy - The sales team for the promotion of atropine has over 500 members, focusing on disease education and product promotion through professional associations [4] - The product has been widely adopted in public hospitals and major private eye care groups, with distribution in nearly 17,000 retail pharmacies and online platforms [5] Research and Development - The company is advancing its innovative product pipeline, including the SQ-22031 eye drops, which are in Phase II clinical trials for neurotrophic keratitis [6] - The 0.01% atropine eye drops have been approved for market entry, with ongoing development of different concentrations (0.02% and 0.04%) for myopia control [5][17] Market Outlook - The near-sighted population among school-aged children in China exceeds 100 million, indicating a vast market potential for myopia prevention products [17] - The company plans to enhance its marketing strategies and expand its market share through comprehensive disease education and collaboration with various stakeholders [10][17] Sales Channels and Distribution - The company employs a multi-channel strategy, integrating both hospital and retail pharmacy sales to improve drug accessibility [9] - The sales contribution from public and private hospitals is crucial, while retail pharmacies and online platforms support patient repurchase [9][10] Future Development Plans - The company is focusing on establishing a new R&D center aimed at enhancing its capabilities in ophthalmic drug development [18] - Plans to expand into international markets are in preliminary discussions, with a focus on maintaining a stable pricing strategy for atropine despite emerging competition [15][13]